184 related articles for article (PubMed ID: 29378547)
1. The Research and Evaluation of Antipsychotic Treatment in Community Behavioral Health Organizations, Outcomes (REACH-OUT) study: real-world clinical practice in schizophrenia.
Joshi K; Mao L; Biondi DM; Millet R
BMC Psychiatry; 2018 Jan; 18(1):24. PubMed ID: 29378547
[TBL] [Abstract][Full Text] [Related]
2. Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.
Pilon D; Tandon N; Lafeuille MH; Kamstra R; Emond B; Lefebvre P; Joshi K
Clin Ther; 2017 Oct; 39(10):1972-1985.e2. PubMed ID: 28919292
[TBL] [Abstract][Full Text] [Related]
3. Factors Associated with the Initiation of Long-Acting Injectable Paliperidone Palmitate Versus Aripiprazole Among Medicaid Patients with Schizophrenia: An Observational Study.
Cai Q; Patel C; Kim E; Connolly N; Tunceli O; El Khoury AC
Adv Ther; 2019 Apr; 36(4):858-869. PubMed ID: 30848442
[TBL] [Abstract][Full Text] [Related]
4. Healthcare resource utilization of second-generation long-acting injectable antipsychotics in schizophrenia: risperidone versus paliperidone palmitate.
Joshi K; Pan X; Wang R; Yang E; Benson C
Curr Med Res Opin; 2016 Nov; 32(11):1873-1881. PubMed ID: 27479694
[TBL] [Abstract][Full Text] [Related]
5. Antipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge.
Marcus SC; Zummo J; Pettit AR; Stoddard J; Doshi JA
J Manag Care Spec Pharm; 2015 Sep; 21(9):754-68. PubMed ID: 26308223
[TBL] [Abstract][Full Text] [Related]
6. Cognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized, pilot trial.
Takekita Y; Koshikawa Y; Fabbri C; Sakai S; Sunada N; Onohara A; Nishida K; Yoshimura M; Kato M; Serretti A; Kinoshita T
BMC Psychiatry; 2016 May; 16():172. PubMed ID: 27236412
[TBL] [Abstract][Full Text] [Related]
7. Comparison and predictors of treatment adherence and remission among patients with schizophrenia treated with paliperidone palmitate or atypical oral antipsychotics in community behavioral health organizations.
Anderson JP; Icten Z; Alas V; Benson C; Joshi K
BMC Psychiatry; 2017 Oct; 17(1):346. PubMed ID: 29047368
[TBL] [Abstract][Full Text] [Related]
8. Economic analysis of paliperidone long-acting injectable for chronic schizophrenia in Portugal.
Einarson TR; Maia-Lopes S; Goswami P; Bereza BG; Van Impe K
J Med Econ; 2016 Sep; 19(9):913-21. PubMed ID: 27124697
[TBL] [Abstract][Full Text] [Related]
9. Treatment discontinuation of long-acting injectables or oral atypical antipsychotics among Medicaid recipients with schizophrenia.
Song X; El Khoury AC; Brouillette M; Smith D; Joshi K
J Med Econ; 2019 Nov; 22(11):1105-1112. PubMed ID: 31062998
[No Abstract] [Full Text] [Related]
10. Clinical effectiveness and resource utilization of paliperidone ER for schizophrenia: Pharmacoepidemiologic International Longitudinal Antipsychotic Registry (PILAR).
Schreiner A; Hargarter L; Hitschfield K; Lee JI; Lenskaya I; Sulaiman AH; Diels J;
Curr Med Res Opin; 2014 Jul; 30(7):1279-89. PubMed ID: 24597755
[TBL] [Abstract][Full Text] [Related]
11. Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France.
Druais S; Doutriaux A; Cognet M; Godet A; Lançon C; Levy P; Samalin L; Guillon P
Pharmacoeconomics; 2016 Apr; 34(4):363-91. PubMed ID: 26883132
[TBL] [Abstract][Full Text] [Related]
12. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia.
Li H; Rui Q; Ning X; Xu H; Gu N
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun; 35(4):1002-8. PubMed ID: 21315787
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Paliperidone Palmitate and Risperidone Long-Acting Injection in Schizophrenic Patients: Results From a Multicenter Retrospective Cohort Study in France.
Limosin F; Belhadi D; Comet D; Pacou M; Bouju S; Van Impe K; Guillon P
J Clin Psychopharmacol; 2018 Feb; 38(1):19-26. PubMed ID: 29232310
[TBL] [Abstract][Full Text] [Related]
14. Once-monthly paliperidone palmitate compared with conventional and atypical daily oral antipsychotic treatment in patients with schizophrenia.
Kim E; Correll CU; Mao L; Starr HL; Alphs L
CNS Spectr; 2016 Dec; 21(6):466-477. PubMed ID: 27629292
[TBL] [Abstract][Full Text] [Related]
15. Recovery outcomes of schizophrenia patients treated with paliperidone palmitate in a community setting: patient and provider perspectives on recovery.
Williams W; McKinney C; Martinez L; Benson C
J Med Econ; 2016; 19(5):469-76. PubMed ID: 26671481
[TBL] [Abstract][Full Text] [Related]
16. Paliperidone palmitate versus risperidone long-acting injection in markedly-to-severely ill schizophrenia subjects: onset of efficacy with recommended initiation regimens.
Fu DJ; Bossie CA; Kern Sliwa J; Ma YW; Alphs L
Clin Schizophr Relat Psychoses; 2014 Jul; 8(2):101-9, 109A. PubMed ID: 23446197
[TBL] [Abstract][Full Text] [Related]
17. Letter to the Editor: Rethinking The Cost Of Antipsychotic Treatment: The Average Cost Of The Drugs Used In Turkey In 2020.
Yıldız M; Osman E
Turk Psikiyatri Derg; 2022; 33(2):146-148. PubMed ID: 35730516
[TBL] [Abstract][Full Text] [Related]
18. Noninterventional, Naturalistic, Retrospective Study to Describe Prescription Patterns of Long-Acting Injectable Antipsychotics and the Impact of Introducing a New Atypical Antipsychotic in the Spanish Province of Tarragona Catchment Area.
Gaviria AM; Franco J; Rico G; Muntané G; Sáez C; Sánchez-Gistau V; de Pablo J; Vilella E
Prim Care Companion CNS Disord; 2017 Mar; 19(2):. PubMed ID: 28346773
[TBL] [Abstract][Full Text] [Related]
19. Retrospective Analysis of the Effectiveness and Tolerability of Long-Acting Paliperidone Palmitate Antipsychotic in Adolescent First-Episode Schizophrenia Patients.
Petrić D; Rački V; Gačo N; Kaštelan A; Graovac M
J Child Adolesc Psychopharmacol; 2019 Apr; 29(3):197-204. PubMed ID: 30758986
[TBL] [Abstract][Full Text] [Related]
20. Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder.
Greene M; Yan T; Chang E; Hartry A; Touya M; Broder MS
J Med Econ; 2018 Feb; 21(2):127-134. PubMed ID: 28895758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
